EXCLUSIVE: Adial Pharmaceuticals Tells Benzinga 'Allowed claims cover the detection of select genotypes for use of AD04 to treating AUD and OUD patients'
Portfolio Pulse from Benzinga Newsdesk
Adial Pharmaceuticals has announced that its allowed claims cover the detection of select genotypes for the use of AD04 in treating Alcohol Use Disorder (AUD) and Opioid Use Disorder (OUD) patients.
October 19, 2023 | 2:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Adial Pharmaceuticals' announcement about its allowed claims covering the use of AD04 for treating AUD and OUD patients could potentially boost investor confidence.
The announcement by Adial Pharmaceuticals about its allowed claims covering the use of AD04 for treating AUD and OUD patients is directly related to the company's core business. This could potentially boost investor confidence in the company and its products, leading to a positive impact on its stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100